~~<i id='66C5775431'><strike id='66C5775431'><tt id='66C5775431'><pre id='66C5775431'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：fashion 2025-08-29 12:59:14 Page View：4

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： A Q&A with Aletha Maybank, AMA’s chief health equity officer
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

DavidLRyan/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

In search for therapies for solid tumors, companies turn to claudin

MollyFergusonforSTATOnTargetisarecurringfeaturefromSTATthatdivesdeepintothemostpromisingdrugtargetsi